Abstract
Background The PROMISE study was launched in 2018 to assess revisions to an HIV care coordination program (CCP) designed to address gaps in care and treatment engagement among people living with HIV in New York City (NYC). We report on the heterogeneity of provider preferences regarding a revised CCP elicited from a discrete choice experiment (DCE).
Methods From January to March 2020, 152 CCP providers in NYC completed a DCE with 4 program attributes: 1) help with adherence to antiretroviral therapy, 2) help with primary care appointments, 3) help with issues other than primary care, and 4) program visit location. Each attribute had 3-4 levels. Latent class analysis (LCA) was used to detect subgroups with differing attribute importance and part-worth utility patterns. Choice simulation was used to estimate providers’ endorsement of eight hypothetical CCPs.
Results LCA identified three subgroups. The two larger subgroups (n = 133) endorsed more intensive attribute levels, particularly clients receiving directly observed therapy, and home visits. The remaining smaller subgroup (n = 19) endorsed clients receiving medication reminders and meeting with clients at the program. Simulation showed that intensive medical case management programs had the highest degree of endorsement (62%).
Conclusion While our results indicate high endorsement among providers for intensive CCP features, overall, they also suggest the need for flexible service delivery options to meet the needs of the clients that these programs serve. Additional information sharing across and within agencies may be warranted to improve the fidelity with which the CCP is implemented.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Institutes of Health (NIH), grant number R01 MH117793.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board of NYC Health Department gave approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email addresses of authors: CF: chunki.fong{at}sph.cuny.edu
MC: madellena.conte{at}sph.cuny.edu
RZ: rebecca.zimba{at}sph.cuny.edu
JC: jcarmona{at}health.nyc.gov
GG: ggambone1{at}health.nyc.gov
ABL: abigail.baim-lance{at}sph.cuny.edu
MR: mckaylee.robertson{at}sph.cuny.edu
MI: mirvine{at}health.nyc.gov
DN: denis.nash{at}sph.cuny.edu
Data Availability
All data produced in the present study are available upon reasonable request to the authors
